What insurance policy changes affect HCPCS J9048?

There are 6 tracked policy changes affecting HCPCS J9048, including updates from Aetna, Humana. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J9048?

Payers that have issued tracked updates for HCPCS J9048 include: Aetna, Humana.

How do I get notified when HCPCS J9048 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J9048. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J9048?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J9048 — Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg: Insurance Policy Changes

J9048 Insurance Policy Changes

HCPCS J9048 is officially defined as "Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg." HCPCS J9048 is referenced in 6 tracked payer policy changes from Aetna and Humana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9048 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Bendamustine products (Treanda, Bendeka, Belrapzo, Vivimusta) (Revised)

Humana·Effective Jan 1, 2026

Humana Louisiana Medicaid updated its prior authorization policy for bendamustine products (Treanda, Bendeka, Belrapzo, Vivimusta) effective January 1, 2026, with a revision date of May 1, 2026. The policy establishes specific approval criteria for five indications (CLL, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, and Waldenström's Macroglobulinemia), with a universal exclusion: members experiencing disease progression on bendamustine-containing regimens are not approved. All bendamustine requests now require prior authorization before dispensing.

J9048 Insurance Policy Changes

Belantamab Mafodotin-blmf (Blenrep) (CPB 0981, reviewed 2026-02-06)

Ciltacabtagene Autoleucel (Carvykti) (CPB 1007, reviewed 2026-03-13)

Elotuzumab (Empliciti) (CPB 0899, reviewed 2026-03-02)

Carfilzomib (Kyprolis) (CPB 0845, reviewed 2026-03-02)

Bendamustine products (Treanda, Bendeka, Belrapzo, Vivimusta) (Revised)

Elranatamab-bcmm (Elrexfio) (CPB 1040, reviewed 2025-12-10)